Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study
Author:
Funder
Novartis
Publisher
Springer Science and Business Media LLC
Subject
Nephrology,Pediatrics, Perinatology, and Child Health
Link
http://link.springer.com/article/10.1007/s00467-018-4003-6/fulltext.html
Reference45 articles.
1. Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, van den Ouweland A (2005) Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype—phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur J Hum Genet 13:731–741
2. Curatolo P, Bombardieri R, Jozwiak S (2008) Tuberous sclerosis. Lancet 372:657–668
3. Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q, Wallace DP, Weimbs T, Wuthrich RP (2010) Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol 5:1312–1329
4. De Waele L, Lagae L, Mekahli D (2015) Tuberous sclerosis complex: the past and the future. Pediatr Nephrol 30:1771–1800
5. Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF, Thiele EA (2006) Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int 70:1777–1782
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice;Orphanet Journal of Rare Diseases;2023-12-02
2. Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition;American Journal of Kidney Diseases;2023-12
3. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice;2023-08-11
4. Multidisciplinary Outpatient Clinic of Neurocutaneous Diseases: Five-year Experience of a Pediatric Tertiary Hospital in Portugal;Acta Médica Portuguesa;2023-06-09
5. Surgical Management of Hereditary Kidney Cancer Syndromes;Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3